Recurrence · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
It is very uncertain whether oral drug treatment changes primary outcome 2: Clinical recurrence at 12 months compared with topical drug treatment (very low certainty).
1 finding from 1 review
Primary outcome 3: Adverse events · non‐pregnant women with a diagnosis of recurrent vulvovaginal candidiasis
1 finding from 1 review
Change in disability score · children with SMA type II
1 finding from 1 review
Muscle strength · children with SMA type II
1 finding from 1 review
Acquiring the ability to stand or walk · children with SMA type II
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in quality of life · children with SMA type II
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in pulmonary function · children with SMA type II
1 finding from 1 review
Time from beginning of treatment until death or full‐time ventilation · children with SMA type II
1 finding from 1 review
Adverse events related to treatment · children with SMA type II
Oral phenylbutyrate probably leads to higher adverse events related to treatment compared with placebo (moderate certainty).
1 finding from 1 review
Mean blood loss (mL) visual estimation · women in the third stage of labour
1 finding from 1 review
Maternal blood loss of 500 mL or greater · women in the third stage of labour
Oral ergot alkaloids showed no clear difference in estimated or measured blood loss of at least 500 mL visual estimation compared with no uterotonic agents (low certainty).
1 finding from 1 review
Severe PPH (≥ 1000 mL) · women in the third stage of labour
Oral ergot alkaloids showed no clear difference in estimated or measured blood loss of at least 1000 mL visual estimation compared with no uterotonic agents (low certainty).
1 finding from 1 review
Haemoglobin (g/dL) · women in the third stage of labour
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Use of therapeutic uterotonics · women in the third stage of labour
Oral ergot alkaloids showed no clear difference in use of therapeutic uterotonics compared with no uterotonic agents (low certainty).
1 finding from 1 review
Elevation of blood pressure · women in the third stage of labour
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain after birth requiring analgesia (not prespecified) · women in the third stage of labour
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of patients with resolution or improved symptoms at days 3 to 7 · patients with acute sinusitis
Oral corticosteroids probably leads to higher proportion of patients with resolution or improved symptoms at days… compared with placebo or NSAID (moderate certainty).
3 findings from 1 review
RR 1.33 [1.09, 1.62]
5 studies · 1043 participants
Moderate
RR 1.4 [1.08, 1.81]
4 studies · 869 participants
Low
RR 1.12 [0.87, 1.44]
1 study · 174 participants
Moderate
Proportion of patients with resolution or improved symptoms at days 4 to 14 · patients with acute sinusitis
Oral corticosteroids probably leads to higher proportion of patients with resolution or improved symptoms at days… compared with placebo or NSAID (moderate certainty).
2 findings from 1 review
Proportion of patients with resolution or improved symptoms at days 4 to 14 ‐ Co‐treatment with antibiotics · patients with acute sinusitis
Oral corticosteroids may leads to higher proportion of patients with resolution or improved symptoms at days… compared with placebo or NSAID (low certainty).
1 finding from 1 review
Adverse events · patients with acute sinusitis
1 finding from 1 review